BioCryst Pharmaceuticals, Inc. Stock News

— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Rec...

—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients' individual needs and preferences—

—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug ...

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — ...